Frontier Biotechnologies Inc. (SHA:688221)

Market Cap	9.25B +153.1%
Revenue (ttm)	141.20M +5.6%
Net Income	-167.73M
EPS	-0.45
Shares Out	374.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,294,600
Average Volume	12,670,069
Open	27.12
Previous Close	n/a
Day's Range	23.63 - 27.12
52-Week Range	7.16 - 29.98
Beta	1.17
RSI	55.77
Earnings Date	Mar 31, 2026

About Frontier Biotechnologies

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and me...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 524
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688221

Financial Performance

In 2024, Frontier Biotechnologies's revenue was 129.47 million, an increase of 13.32% compared to the previous year's 114.25 million. Losses were -201.38 million, -38.78% less than in 2023.